Table 1.
Demographic Data.
| Characteristic | Value |
|---|---|
| No. of patients | 26 eyes of 25 patients (1 bilateral case) |
| Sex, No. (%) | |
| Female | 22 (88) |
| Male | 3(12) |
| Age, y, mean (range) | 79.1 (58–92) |
| Eye, No. of eyes (%) | |
| Right | 13 (50) |
| Left | 13 (50) |
| Race, No. (%) | |
| White | 24 (96) |
| Black | 1 (4) |
| Location, No. | |
| United States | 25 |
| Northeast | 8 |
| Western | 7 |
| Southern | 6 |
| Midwest | 4 |
| Autoimmune history, No. (%) | 5 (20): Multiple sclerosis Raynaud disease and hypothyroidism Graves disease Hypothyroidism and psoriasis History of iritis |
| Drug allergies, No. (%) | |
| No allergies | 14 (56%) |
| No pattern | 11 (44%) |
| Lens, No. of eyes (%) | |
| Phakic | 5(19) |
| Pseudophakic | 21 (81) |
| Months of NVAMD diagnosis prior to brolucizumab, No. (range) | 54.5 (4–138) |
| No. of prior anti-VEGF injections (before brolucizumab) | |
| Mean (range) | 39.1 (2–78) |
| Total | 1018 |
| Type of injections prior to brolucizumab, % | |
| Ranibizumab | 16 |
| Bevacizumab | 23 |
| Aflibercept | 61 |
| Most recent injection prior to brolucizumab, No. (%) | |
| Ranibizumab | 1 (4) |
| Bevacizumab | 6 (23) |
| Aflibercept | 19(73) |
| Days between last anti-VEGF and first brolucizumab, No. (range) | 43.4(19–111) |
| Reason to switch to brolucizumab, No. of eyes (%) | |
| Extend treatment interval Improve efficacy | 20 (77) |
| Worsening vision despite monthly | 19(73) |
| injections | 1 (4) |
Abbreviations: anti-VEGF, antivascular endothelial growth factor; NVAMD, neovascular age-related macular degeneration.